首页|免疫介导的肝炎研究进展

免疫介导的肝炎研究进展

扫码查看
近年来,以程序性死亡受体 1(PD-1)抗体、程序性死亡配体 1(PD-L1)抗体和细胞毒性T淋巴细胞相关抗原 4(CTLA-4)抗体为代表的免疫检查点抑制剂(ICIs)彻底改变了肿瘤治疗.然而,伴随着涉及多个器官的免疫相关不良反应.肝脏不断暴露于外来抗原,已经进化出很高的免疫耐受能力.本文主要综述与免疫介导的肝炎相关的CTLA-4、ICIs、肝脏免疫耐受及免疫介导的肝炎发生机制的研究进展.
Research Progress on Immune-mediated Hepatitis
In recent years,immune checkpoint inhibitors(ICIs)represented by antibodies against programmed death receptor 1(PD-1),programmed death ligand 1(PD-L1),and cytotoxic T lymphocyte associated antigen 4(CTLA-4)have completely revolutionized tumor therapy.However,it is accompanied by immune related adverse reactions involving multiple organs.The liver is constantly exposed to foreign antigens and has evolved a high immune tolerance.This article mainly reviews the research progress on CTLA-4,ICIs,liver immune tolerance,and immune mediated hepatitis mechanisms related to immune mediated hepatitis.

Immune-mediated hepatitisImmunotherapyImmune checkpoint inhibitors

皮加、曹冠柏、刘先齐

展开 >

重庆市九龙坡区人民医院外科 重庆 400050

免疫介导的肝炎 免疫治疗 免疫检查点抑制剂

2024

中国医学创新
中国保健协会

中国医学创新

影响因子:1.706
ISSN:1674-4985
年,卷(期):2024.21(13)
  • 25